Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.

Antimicrobial agents and chemotherapy - 1 Apr 2002

Harrigan P R, Miller M D, McKenna P, Brumme Z L, Larder B A

Abstract excerpt

Tenofovir is a nucleotide analogue human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) inhibitor, and its oral prodrug, tenofovir disoproxil fumarate, has recently been approved for the treatment of HIV-1 infection in the United States. The objective of this study was to charac...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to RNA, Viral
Share to Adenine
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Organophosphonates

Share to Organophosphorus Compounds

Share to Reverse Transcriptase Inhibitors

Share to Tenofovir

Source

Open in PubMed Open full text

Identifiers

PMID: 11897591
DOI: 10.1128/AAC.46.4.1067-1072.2002
PMCID: PMC127100

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-11897591-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.PMID 11897591Read ↗

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.Semantic proximity Read ↗

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.Semantic proximity Read ↗

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.Semantic proximity Read ↗

Tenofovir, Adefovir, and Zidovudine Susceptibilities of Primary Human Immunodeficiency Virus Type 1 Isolates with Non-B Subtypes or Nucleoside ResistanceSemantic proximity Read ↗

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.Semantic proximity Read ↗

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.Semantic proximity Read ↗

Susceptibility testing. Viral pathogens.Semantic proximity Read ↗

Tenofovir disoproxil fumarate.Semantic proximity Read ↗

Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays.Semantic proximity Read ↗

Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.Semantic proximity Read ↗

Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.Semantic proximity Read ↗

In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.